Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Eligibility Criteria

• 1. Histologically proven metastatic adenocarcinoma of the colon or rectum.
• 1. Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.
• 2. Confirmed non-microsatellite instability high (non-MSI-H)/mismatch-repair proficient (pMMR) tumor status
• 3. Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
• 4. Recurrent/progressing disease after at least one line of systemic therapy for metastatic disease which must include FOLFOX chemotherapy
• 5. The patient is due to receive FOLFOX chemotherapy
• 6. Neurotoxicity less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 from previous chemotherapy.
• 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• 3. Adequate organ, hepatic, renal, pulmonary and cardiac functions
• 4. Tumor biopsy at screening
• 1. Any other investigational agent or device within 4 weeks of the first study treatment administration.
• 2. Any anticancer agent within 4 weeks of the first study treatment administration
• 3. Filgrastim (Granulocyte-Colony-Stimulating Factor \[G-CSF\]) or similar growth factors within 7 days of the first study treatment administration
• 4. Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
• 5. Prior radiotherapy within 2 weeks prior to the planned day for the first study treatment administration
• 6. Major surgery within 4 weeks before the planned day for the first study treatment administration
• 7. A live vaccine within 30 days prior to the planned day for the first study treatment administration
• 8. Uncontrolled intercurrent illness or serious uncontrolled medical disorder
• 9. Patients with history of (non-infectious) pneumonitis that require steroids or has current pneumonitis as assessed by chest imaging within 48 hours prior to first study treatment administration.